Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim GMBH

www.boehringer-ingelheim.com

Latest From Boehringer Ingelheim GMBH

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals

Market Intel: Digital Tech At The Heart Of Cardiology Innovation

Digital health technologies from smartphone applications, wearables, digital weight scales and telehealth are rapidly changing the landscape of cardiac care, offering new tools for engaging cardiology patients and enhancing cardiologists' workflows. There is a lot of hype, but also some real promise. Here's a look at what's happening and some expert insights on the benefits and challenges these new innovations represent, as well as market projections. Digital health was a major topic of discussion by cardiologists and entrepreneurs during this year's Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. This is the second in a series of articles on the future of cardiovascular technology, spotlighting discussion and presentations from TCT.

Digital Health Cardiology

Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars

Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.
Biosimilars United Kingdom

AbbVie's Fourth Humira Patent Settlement Allows Sandoz Biosimilar US Entry Eight Months After Amgen

Sandoz joins list of companies that opt to settle rather than challenge AbbVie's hefty patent portfolio; staggered launches offer model for future deals.

Biosimilars Intellectual Property
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register